ProductsDispensing a Bright Future
With a team of 400+ of the finest manufacturing, engineering and quality professionals from across the country, Innoxel, along with its development partners is currently building a portfolio of several complex generics including long acting injections, liposomal formulations, first time oral liquid forms of products with dosing and titration challenges and an NDA portfolio comprising long-acting forms of already approved USFDA drugs in therapeutic areas resolving several clearly established key patient compliance and adherence challenges associated with the present standard of care.
